Ampametry

Ampametry is a preclinical-stage biotechnology company focused on discovering and developing novel small molecule therapeutics for central nervous system (CNS) disorders. The company's core technology centers on the modulation of AMPA receptors, which are critical mediators of fast excitatory synaptic transmission in the brain. By targeting Transmembrane AMPA receptor Regulatory Proteins (TARPs), Ampametry aims to achieve unprecedented selectivity in tuning synaptic activity, potentially avoiding the side effects associated with broad-spectrum glutamate modulators. The company was founded by world-renowned experts in synaptic pharmacology and is currently advancing a pipeline of programs for indications such as epilepsy and treatment-resistant depression. Ampametry leverages a proprietary screening platform to identify compounds that act in a synapse-specific manner. This approach represents a significant advancement in the field of neuropharmacology, aiming to restore balance to dysfunctional neural circuits.